about
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsRevisiting the case for genetically engineered mouse models in human myelodysplastic syndrome researchNew strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practicePhase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyPredicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias.Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineThe small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cellsIdarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.Stopping higher-risk myelodysplastic syndrome in its tracks.Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes.Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice.Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support.Trial watch: Chemotherapy with immunogenic cell death inducers.Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
P2860
Q26745731-1A221103-CA01-42C5-9FC1-94F21492A8C8Q26859843-F41697BA-9ABD-4D36-9117-A9C54F61A1C6Q27016511-1EA10791-08E4-4A08-A4D6-9898F9F4E579Q33390778-87339C07-0AC8-46F2-90EA-61D795C4225AQ33405470-6E16F000-2684-4EE5-A77B-644B11D26D38Q33987086-BB901A46-3BAA-4E80-A121-5DE73FDC636AQ33999887-D0F20B85-CAB7-4C75-B5E4-A44C5FADCD05Q34273735-14E6DEE9-533D-4CE6-A797-58B5C020E9D9Q35265820-A123B0B0-0121-4B83-9B8C-E85FE357BBF5Q35926555-430157A6-246A-495D-846D-4795F3747E3FQ35935802-D3C29D67-3E44-44D9-9A14-B60B4CA6462AQ36029093-68BF9A9B-86A9-4D48-8675-0FE5D0DEAA9AQ36133037-BB437BE7-8392-483C-AF57-744E359DAA55Q36158816-7AAE2D58-546A-469C-8078-5FD94935BF2AQ36692756-18DF3273-C44C-40A5-9C8B-ECE3CD4BD1C8Q36877036-2E44E83B-7B95-41D3-8672-322E3A672CC5Q37282218-59C30D4F-D82E-4B32-821A-A0A80A8696B2Q37702336-635246A4-0BE0-441D-B0E0-FD05ED811976Q37824712-6F04F880-F70D-44BE-A2B3-4304B5EF6F42Q38248180-214FD7FC-221B-481B-93F1-D4011EAB94BAQ39069010-504B5ED4-0845-4FC1-B11E-9B0088C4EF65Q39069357-61311362-F89C-416A-8ECB-F14CD65D6AB2Q39970255-130DF95B-196B-4E92-894F-C9E46E5F97FDQ40648327-E72F534F-507F-41EC-BD78-2DBFDE5B7CDBQ41640013-DC36D2E6-FE05-4DEE-97A9-4D1C80914D66Q41956956-96296812-A400-44B1-858B-FA954FB07360Q46093609-EEB34870-1EBE-4162-B138-6EE1219A0BC2Q50506069-60C2F283-E5DE-4801-9B8D-49837AF0BE12Q50545368-11896ABA-310F-4C4E-99B2-50D97349C4ADQ55658029-EA59E64A-E746-49BC-819A-9DBF420BA987Q58706592-EEB52DFC-0FF5-4F7A-B9BE-8939C2986056
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How I treat patients with myelodysplastic syndromes.
@en
How I treat patients with myelodysplastic syndromes.
@nl
type
label
How I treat patients with myelodysplastic syndromes.
@en
How I treat patients with myelodysplastic syndromes.
@nl
prefLabel
How I treat patients with myelodysplastic syndromes.
@en
How I treat patients with myelodysplastic syndromes.
@nl
P1433
P1476
How I treat patients with myelodysplastic syndromes.
@en
P2093
Richard M Stone
P304
P356
10.1182/BLOOD-2008-09-038935
P407
P577
2009-04-21T00:00:00Z